BridgeBio Oncology Therapeutics, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $49.2M | — | $39.8M | — | $38.1M | — | $35.1M |
| SG&A Expense | — | $11.0M | — | $6.4M | — | $5.3M | — | $14.1M |
| Operating Income | — | $-60.2M | — | $-46.2M | — | $-43.4M | — | $-49.2M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | — | — | — | — | — | $0 |
| Net Income | — | $-56.5M | — | $-42.1M | — | $-38.8M | — | $-44.8M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-705.20 | — | $-526.11 | — | $-0.49 | — | $0.00 |
| EPS (Diluted) | — | $-705.20 | — | $-526.11 | — | $-0.49 | — | $0.00 |
| Shares Outstanding (Basic) | 80.2M | 80.1M | 80.1M | 80.0K | 80.0M | 80.0M | 193.09B | 104.99B |
| Shares Outstanding (Diluted) | 80.2M | 80.1M | 80.1M | 80.0K | 80.0M | 80.0M | 193.09B | 104.99B |
| Dividends Per Share | — | — | — | — | — | — | — | — |